# Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis

Study · id `cardio:ct-nct01195246` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01195246](<https://clinicaltrials.gov/study/NCT01195246>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01195246

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 155 participants.

## Technical summary

Registry record NCT01195246. Randomized; triple masking; primary purpose prevention. Start 2010-12 (registry gives no type); primary completion 2012-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 155 participants (enrolled count; ClinicalTrials.gov record NCT01195246, source copy `cardio:ctgov-nct01195246-2019-03-20`, retrieved 2026-10-26)
- Start date: 2010-12 (registry gives no type) (ClinicalTrials.gov record NCT01195246, source copy `cardio:ctgov-nct01195246-2019-03-20`, retrieved 2026-10-26)
- Primary completion: 2012-02 (actual) (ClinicalTrials.gov record NCT01195246, source copy `cardio:ctgov-nct01195246-2019-03-20`, retrieved 2026-10-26)
- Completion: 2012-08 (actual) (ClinicalTrials.gov record NCT01195246, source copy `cardio:ctgov-nct01195246-2019-03-20`, retrieved 2026-10-26)
- Countries: Germany (ClinicalTrials.gov record NCT01195246, source copy `cardio:ctgov-nct01195246-2019-03-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01195246-2019-03-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis
- Condition: End Stage Renal Disease
- Intervention (Biological): HEPLISAV
- Intervention (Biological): Engerix-B
- Intervention (Biological): Fendrix
- Lead sponsor: Dynavax Technologies Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: 14970a2b865bf0dafe0f6ded1a308ecbd191e04989299366d24a9d855e07f13a
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
